Lifetime progesterone (P4) exposure is an important contributor to breast cancer risk, as reflected in the risk associated with the lifetime number of ovulatory cycles, increased breast epithelial proliferation accompanying the P4 peak in the luteal phase, and the higher breast cancer risk of exogenous progestin users. Moreover, the tumors seen with progestin use appear to be more aggressive. This clinical and epidemiological evidence points to progesterone blockade as an excellent candidate strategy for breast cancer prevention. A new generation of selective progesterone receptor modulators (SPRMs) is now available; one of these (telapristone acetate, TPA) inhibits P4-driven proliferation of breast cancer cells, and attenuates P4-driven tumor growth in carcinogen treated rats. We have identified a novel set of genes associated with proliferation of breast cancer cells in response to the progestin, R5020 that are effectively suppressed by TPA. Based on these data as well as findings from others, we hypothesize that P4 promotes a pro-proliferative and tumor permissive phenotype which supports breast cancer development, suppression of which by SPRMs will significantly decrease breast cancer risk. The breast-specific effects and mechanisms for potential breast cancer protection of SPRMs are unknown. We propose to define the mechanisms by which SPRMs antagonize PR at the molecular level, and the role of coactivators and corepressors. In addition, the efficacy of SPRMs in antagonizing the proliferative response to P4 will be determined, to guide selection of patients for SPRM therapy.
In Aim 1, we will determine the mechanisms by which SPRMs regulate PR activity in breast cells. The ability of SPRMs to affect binding to the PR will be studied; we will perform ChIP-Seq to determine how SPRMs affect PR recruitment to the genome in a global manner, and the involvement of the nuclear receptor corepressors, NCOR and SMRT as well as other transcription cofactors will be assessed.
In Aim 2, we will determine if SPRMs inhibit the P4-mediated tumor permissive phenotype; we have defined a 16 gene panel, which is associated with P4 driven proliferation. We will test this in vitro, in human mammary organoids, to determine whether SPRMs inhibit expression of these signature genes. We will also study the ability of SPRMs to inhibit mammary stem cell expansion associated with P4 exposure, and the proliferation and growth of tumors that carry BRCA1 mutations.
In Aim 3, we will evaluate the expression P4-response genes in human clinical samples, a) in high and low ambient progesterone environments and b) following treatment with telapristone acetate. These experiments will 1) define modes of actions of SPRMs in cells and tissues where PR signaling is active, 2) relate inhibition of proliferation of breast cells, and of stem cell expansion, to speciic genetic pathways; and 3) demonstrate utility of these markers in human breast samples. These results will significantly advance the field of breast cancer prevention in novel directions, providing both new, effective agents, particularly for premenopausal women.

Public Health Relevance

Exposure to progesterone and progestins has been implicated in the promotion of breast cancer. Blockade of progesterone/progestin signaling is therefore an attractive candidate strategy for breast cancer prevention, and possibly for therapy of early breast cancer. We propose to test selective progesterone receptor modulators for this purpose through a series of laboratory experiments in cell lines and animals, and finally in human breast tissue.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA192124-01A1
Application #
8963820
Study Section
Chemo/Dietary Prevention Study Section (CDP)
Program Officer
Dunn, Barbara K
Project Start
2015-08-03
Project End
2020-07-31
Budget Start
2015-08-03
Budget End
2016-07-31
Support Year
1
Fiscal Year
2015
Total Cost
$378,871
Indirect Cost
$133,647
Name
Northwestern University at Chicago
Department
Surgery
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Davaadelger, Batzaya; Murphy, Alina R; Clare, Susan E et al. (2018) Mechanism of Telapristone Acetate (CDB4124) on Progesterone Receptor Action in Breast Cancer Cells. Endocrinology 159:3581-3595
Clare, Susan E; Gupta, Akash; Choi, MiRan et al. (2016) Progesterone receptor blockade in human breast cancer cells decreases cell cycle progression through G2/M by repressing G2/M genes. BMC Cancer 16:326